These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19325276)

  • 1. Analysis of patient cost for recombinant human platelet-derived growth factor therapy as the first-line treatment of the insured patient with a diabetic foot ulcer.
    Lantis JC; Boone D; Gendics C; Todd G
    Adv Skin Wound Care; 2009 Apr; 22(4):167-71. PubMed ID: 19325276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U; Willis M; Odegaard K; Apelqvist J
    Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG
    Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group.
    Steed DL; Donohoe D; Webster MW; Lindsley L
    J Am Coll Surg; 1996 Jul; 183(1):61-4. PubMed ID: 8673309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM; Waycaster CR; Motley TA
    Wound Repair Regen; 2015; 23(3):353-60. PubMed ID: 25810233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR; Gilligan AM; Motley TA
    J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers.
    Margolis DJ; Bartus C; Hoffstad O; Malay S; Berlin JA
    Wound Repair Regen; 2005; 13(6):531-6. PubMed ID: 16283867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic aspects of biofilm-based wound care in diabetic foot ulcers.
    Wolcott R
    J Wound Care; 2015 May; 24(5):189-90, 192-4. PubMed ID: 25970755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H; Supe A
    Indian J Med Sci; 2007 Jun; 61(6):347-55. PubMed ID: 17558098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting healing with recombinant human platelet-derived growth factor--BB in a previously irradiated problem wound.
    Hom DB; Manivel JC
    Laryngoscope; 2003 Sep; 113(9):1566-71. PubMed ID: 12972935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone.
    Nevins M; Camelo M; Nevins ML; Schenk RK; Lynch SE
    J Periodontol; 2003 Sep; 74(9):1282-92. PubMed ID: 14584860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products.
    Gilligan AM; Waycaster CR; Landsman AL
    J Wound Care; 2015 Mar; 24(3):149-56. PubMed ID: 25764960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study.
    Tallis A; Motley TA; Wunderlich RP; Dickerson JE; Waycaster C; Slade HB;
    Clin Ther; 2013 Nov; 35(11):1805-20. PubMed ID: 24145042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced biological therapies for diabetic foot ulcers.
    Kirsner RS; Warriner R; Michela M; Stasik L; Freeman K
    Arch Dermatol; 2010 Aug; 146(8):857-62. PubMed ID: 20713816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes.
    Guest JF; Fuller GW; Vowden P
    Int Wound J; 2018 Feb; 15(1):43-52. PubMed ID: 29243399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O; Persson U; Willis M; Odegaard K
    Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the costs and profitability of care for diabetic foot ulcers treated in a multidisciplinary setting.
    Hicks CW; Canner JK; Karagozlu H; Mathioudakis N; Sherman RL; Black JH; Abularrage CJ
    J Vasc Surg; 2019 Jul; 70(1):233-240. PubMed ID: 30606663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.